Critical Survey: NWT Uranium (OTCMKTS:CPTRF) & Zimmer Biomet (NYSE:ZBH)

Zimmer Biomet (NYSE:ZBH) and NWT Uranium (OTCMKTS:CPTRF) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Institutional & Insider Ownership

88.9% of Zimmer Biomet shares are owned by institutional investors. 1.3% of Zimmer Biomet shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and target prices for Zimmer Biomet and NWT Uranium, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zimmer Biomet	4	12	7	1	2.21
NWT Uranium	0	0	0	0	0.00

Zimmer Biomet currently has a consensus price target of $100.70, suggesting a potential upside of 9.28%. Given Zimmer Biomet’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Zimmer Biomet is more favorable than NWT Uranium.

Profitability

This table compares Zimmer Biomet and NWT Uranium’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zimmer Biomet	9.05%	13.24%	7.28%
NWT Uranium	N/A	-157.37%	-147.81%

Valuation & Earnings

This table compares Zimmer Biomet and NWT Uranium”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zimmer Biomet	$8.23 billion	2.17	$705.20 million	$3.85	23.93
NWT Uranium	$27.25 million	N/A	$6.69 million	$4.08	0.04

Zimmer Biomet has higher revenue and earnings than NWT Uranium. NWT Uranium is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Summary

Zimmer Biomet beats NWT Uranium on 12 of the 13 factors compared between the two stocks.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers robotic, surgical, and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

About NWT Uranium

Captor Capital Corp. engages in the manufacture and retail sale of cannabis products in the United States. It operates two dispensaries under the CHAI Cannabis Co. brand in Santa Cruz and Monterey, California, as well as operates an e-commerce site under the CHAI-brand. The company was formerly known as NWT Uranium Corp. and changed its name to Captor Capital Corp. in June 2017. Captor Capital Corp. was incorporated in 2003 and is based in Toronto, Canada.